Recent News
Aug. 6, 2025 — Lantheus reported second-quarter 2025 results: worldwide revenue $378.0M and GAAP EPS $1.12; management cited completed acquisitions of Evergreen Theragnostics and Life Molecular Imaging, FDA acceptance of an NDA for a new PSMA PET formulation, and a Board authorization of a $400M stock repurchase program. Jul. 23, 2025 — Company scheduled an earnings call for Aug. 6, 2025 to review Q2 results and the business update.
Technical Analysis
ADX reads 41.23, indicating very strong trend strength; this amplifies the near-term significance of directional moves and supports a view that trend-following momentum may carry price action more decisively than in low-ADX environments.
Directional indicators show DI+ at 12.53 with a dip-and-reversal (bullish) while DI- sits at 28.98 and is decreasing (bullish). Together these directional changes align with an improving directional bias that supports a bullish near-term outlook relative to recent price levels.
MACD at -2.43 has completed a dip-and-reversal and stands above its signal line (-2.85), a bullish momentum confirmation; that crossover signals momentum has shifted from more negative readings toward upward pressure on price over the short term.
MRO equals -29.3, negative and in dip-and-reversal, indicating the market price sits below the oscillator’s target and, mechanically, carries potential to move higher as the gap narrows; the magnitude of the negative value implies a notable mean-reversion component.
RSI at 39.35 with a dip-and-reversal describes improving shorter-term momentum from an oversold-biased level; the reading leaves room to climb before entering overbought ranges and supports scope for a swing rally.
Price structure: close $53.23 sits above the 20-day average ($52.56) and the 12-day EMA ($52.41) but well below the 200-day average ($82.47) and below the 50-day average ($59.63). That pattern implies a short-term bias to the upside within a longer-term downshift, with the super trend upper band at $54.93 acting as immediate resistance.
Fundamental Analysis
Profitability and cash flow: EBIT $109,434,000 and EBITDA $122,665,000 support an EBIT margin of 28.95%, which sits above the industry peer mean of 14.45% and above the industry peer median of 20.38%. EBIT margin QoQ rose 6.49% and YoY rose 27.84%, reflecting material margin improvement quarter-over-quarter and year-over-year.
Operating metrics: operating margin measures 23.27% with a QoQ change of -14.40% and YoY change of 2.76%, showing some quarter-to-quarter compression even as year-over-year operating efficiency improved. Total revenue registered $378,045,000.
Liquidity and capital structure: cash and short-term investments $695,572,000 exceed total debt $615,494,000; current ratio 4.29 and cash ratio 2.48 indicate strong near-term liquidity. Debt-to-EBITDA stands at 5.02 while interest coverage reaches 22.26, combining higher leverage on an EBITDA basis with comfortable ability to service interest expense.
Cash generation and valuation metrics: free cash flow $73,732,000 yields 1.58%, above the industry peer mean free cash flow yield of 0.73%. WMDST’s current valuation calls the stock under-valued, which aligns with strong cash balances, positive free cash generation, and above-peer EBIT margin.
Earnings and multiples: reported EPS $1.12 vs. estimate -$0.21 produced an EPS difference of $1.33 and an EPS surprise ratio of 633.33%. Trailing PE equals 71.08 while forward PE reads 49.27; price-to-book 4.01 sits slightly below the industry peer mean book multiple of 4.25. Enterprise-value-to-revenue and enterprise multiple metrics remain elevated relative to broader averages, reflecting growth expectations baked into price.
- Key fundamentals: return on equity 6.75%, return on assets 3.78%, gross margin 63.75%.
- Growth: reported revenue growth figures include YoY movements; management’s completed acquisitions intend to diversify revenue toward PET neurology and theranostics.
Valuation note: WMDST values the stock as under-valued based on current cash generation, margin profile, and balance-sheet liquidity, tempered by elevated leverage on a debt/EBITDA basis and near-term revenue dynamics.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-06-30 |
| REPORT DATE: | 2025-08-06 |
| NEXT REPORT DATE: | 2025-10-28 |
| CASH FLOW | Begin Period Cash Flow | $ 940.2 M |
| Operating Cash Flow | $ 87.1 M | |
| Capital Expenditures | $ -13.37 M | |
| Change In Working Capital | $ -10.93 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ -242.95 M | |
| End Period Cash Flow | $ 697.3 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | $ 378.0 M | |
| Forward Revenue | $ 141.4 M | |
| COSTS | ||
| Cost Of Revenue | $ 137.0 M | |
| Depreciation | $ 13.2 M | |
| Depreciation and Amortization | $ 13.2 M | |
| Research and Development | $ 45.5 M | |
| Total Operating Expenses | $ 290.1 M | |
| PROFITABILITY | ||
| Gross Profit | $ 241.0 M | |
| EBITDA | $ 122.7 M | |
| EBIT | $ 109.4 M | |
| Operating Income | $ 88.0 M | |
| Interest Income | $ 7.2 M | |
| Interest Expense | $ 4.9 M | |
| Net Interest Income | $ 2.3 M | |
| Income Before Tax | $ 104.5 M | |
| Tax Provision | $ 25.8 M | |
| Tax Rate | 24.6 % | |
| Net Income | $ 78.8 M | |
| Net Income From Continuing Operations | $ 78.8 M | |
| EARNINGS | ||
| EPS Estimate | $ -0.21 | |
| EPS Actual | $ 1.12 | |
| EPS Difference | $ 1.33 | |
| EPS Surprise | 633.333 % | |
| Forward EPS | $ 1.73 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 2.1 B | |
| Intangible Assets | $ 536.8 M | |
| Net Tangible Assets | $ 630.0 M | |
| Total Current Assets | $ 1.2 B | |
| Cash and Short-Term Investments | $ 695.6 M | |
| Cash | $ 695.6 M | |
| Net Receivables | $ 336.6 M | |
| Inventory | $ 62.2 M | |
| Long-Term Investments | $ 36.4 M | |
| LIABILITIES | ||
| Accounts Payable | $ 40.9 M | |
| Short-Term Debt | $ 796.0 K | |
| Total Current Liabilities | $ 280.1 M | |
| Net Debt | — | |
| Total Debt | $ 615.5 M | |
| Total Liabilities | $ 949.3 M | |
| EQUITY | ||
| Total Equity | $ 1.2 B | |
| Retained Earnings | $ 597.6 M | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 17.16 | |
| Shares Outstanding | 67.987 M | |
| Revenue Per-Share | $ 5.56 | |
| VALUATION | Market Capitalization | $ 4.7 B |
| Enterprise Value | $ 4.6 B | |
| Enterprise Multiple | 37.459 | |
| Enterprise Multiple QoQ | -33.799 % | |
| Enterprise Multiple YoY | -29.703 % | |
| Enterprise Multiple IPRWA | high: 234.897 median: 76.655 mean: 69.28 LNTH: 37.459 low: -228.246 |
|
| EV/R | 12.154 | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.814 | |
| Asset To Liability | 2.229 | |
| Debt To Capital | 0.345 | |
| Debt To Assets | 0.291 | |
| Debt To Assets QoQ | -2.703 % | |
| Debt To Assets YoY | 64537.778 % | |
| Debt To Assets IPRWA | high: 1.297 LNTH: 0.291 mean: 0.241 median: 0.167 low: 0.002 |
|
| Debt To Equity | 0.528 | |
| Debt To Equity QoQ | -0.045 % | |
| Debt To Equity YoY | 61960.0 % | |
| Debt To Equity IPRWA | high: 2.971 LNTH: 0.528 mean: 0.401 median: 0.266 low: -1.733 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 4.007 | |
| Price To Book QoQ | -31.694 % | |
| Price To Book YoY | -34.714 % | |
| Price To Book IPRWA | high: 19.098 median: 4.499 mean: 4.254 LNTH: 4.007 low: -7.981 |
|
| Price To Earnings (P/E) | 71.077 | |
| Price To Earnings QoQ | 10.121 % | |
| Price To Earnings YoY | 40.937 % | |
| Price To Earnings IPRWA | high: 246.592 median: 104.657 mean: 85.016 LNTH: 71.077 low: -204.468 |
|
| PE/G Ratio | 7.25 | |
| Price To Sales (P/S) | 12.366 | |
| Price To Sales QoQ | -32.498 % | |
| Price To Sales YoY | -22.656 % | |
| Price To Sales IPRWA | high: 154.906 mean: 20.877 median: 20.417 LNTH: 12.366 low: 0.297 |
|
| FORWARD MULTIPLES | ||
| Forward P/E | 49.267 | |
| Forward PE/G | 5.025 | |
| Forward P/S | 33.073 | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | 5.643 | |
| ASSET & SALES | ||
| Asset Turnover Ratio | 0.181 | |
| Asset Turnover Ratio QoQ | -1.884 % | |
| Asset Turnover Ratio YoY | -13.273 % | |
| Asset Turnover Ratio IPRWA | high: 0.482 LNTH: 0.181 mean: 0.159 median: 0.135 low: 0.0 |
|
| Receivables Turnover | 1.103 | |
| Receivables Turnover Ratio QoQ | -0.851 % | |
| Receivables Turnover Ratio YoY | -0.664 % | |
| Receivables Turnover Ratio IPRWA | high: 3.864 mean: 1.495 median: 1.457 LNTH: 1.103 low: 0.477 |
|
| Inventory Turnover | 2.088 | |
| Inventory Turnover Ratio QoQ | 5.993 % | |
| Inventory Turnover Ratio YoY | 5.857 % | |
| Inventory Turnover Ratio IPRWA | high: 2.773 LNTH: 2.088 mean: 0.729 median: 0.714 low: 0.003 |
|
| Days Sales Outstanding (DSO) | 82.71 | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | 98.086 | |
| Cash Conversion Cycle Days QoQ | -2.38 % | |
| Cash Conversion Cycle Days YoY | -2.909 % | |
| Cash Conversion Cycle Days IPRWA | high: 401.407 mean: 139.686 median: 114.45 LNTH: 98.086 low: -252.738 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | 0.41 | |
| CapEx To Revenue | -0.035 | |
| CapEx To Depreciation | -1.011 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 1.7 B | |
| Net Invested Capital | $ 1.7 B | |
| Invested Capital | $ 1.7 B | |
| Net Tangible Assets | $ 630.0 M | |
| Net Working Capital | $ 921.7 M | |
| LIQUIDITY | ||
| Cash Ratio | 2.483 | |
| Current Ratio | 4.29 | |
| Current Ratio QoQ | -25.271 % | |
| Current Ratio YoY | -8.253 % | |
| Current Ratio IPRWA | high: 16.236 LNTH: 4.29 mean: 2.25 median: 1.849 low: 0.353 |
|
| Quick Ratio | 4.068 | |
| Quick Ratio QoQ | -25.52 % | |
| Quick Ratio YoY | -7.712 % | |
| Quick Ratio IPRWA | high: 9.867 LNTH: 4.068 mean: 1.626 median: 1.303 low: 0.411 |
|
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | 5.018 | |
| Cost Of Debt | 0.602 % | |
| Interest Coverage Ratio | 22.256 | |
| Interest Coverage Ratio QoQ | 5.513 % | |
| Interest Coverage Ratio YoY | 21.263 % | |
| Interest Coverage Ratio IPRWA | high: 274.877 mean: 25.468 LNTH: 22.256 median: 15.82 low: -384.45 |
|
| Operating Cash Flow Ratio | 0.382 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | 28.972 | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | 2.961 % | |
| Revenue Growth | 1.417 % | |
| Revenue Growth QoQ | -130.207 % | |
| Revenue Growth YoY | -78.26 % | |
| Revenue Growth IPRWA | high: 40.459 % median: 7.569 % mean: 7.53 % LNTH: 1.417 % low: -31.512 % |
|
| Earnings Growth | 9.804 % | |
| Earnings Growth QoQ | -359.777 % | |
| Earnings Growth YoY | 50.622 % | |
| Earnings Growth IPRWA | high: 200.0 % median: 15.596 % mean: 14.67 % LNTH: 9.804 % low: -227.273 % |
|
| MARGINS | ||
| Gross Margin | 63.752 % | |
| Gross Margin QoQ | -0.024 % | |
| Gross Margin YoY | -1.772 % | |
| Gross Margin IPRWA | high: 94.498 % LNTH: 63.752 % mean: 56.936 % median: 56.435 % low: 6.0 % |
|
| EBIT Margin | 28.947 % | |
| EBIT Margin QoQ | 6.485 % | |
| EBIT Margin YoY | 27.835 % | |
| EBIT Margin IPRWA | high: 33.87 % LNTH: 28.947 % median: 20.382 % mean: 14.452 % low: -1000.426 % |
|
| Return On Sales (ROS) | 23.269 % | |
| Return On Sales QoQ | -14.402 % | |
| Return On Sales YoY | 2.76 % | |
| Return On Sales IPRWA | high: 35.533 % LNTH: 23.269 % median: 18.417 % mean: 12.839 % low: -1349.836 % |
|
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ 73.7 M | |
| Free Cash Flow Yield | 1.577 % | |
| Free Cash Flow Yield QoQ | 8.984 % | |
| Free Cash Flow Yield YoY | 118.119 % | |
| Free Cash Flow Yield IPRWA | high: 11.539 % LNTH: 1.577 % mean: 0.731 % median: 0.679 % low: -40.868 % |
|
| Free Cash Growth | -25.406 % | |
| Free Cash Growth QoQ | -15.527 % | |
| Free Cash Growth YoY | -58.834 % | |
| Free Cash Growth IPRWA | high: 337.277 % mean: 9.289 % median: -1.288 % LNTH: -25.406 % low: -261.538 % |
|
| Free Cash To Net Income | 0.936 | |
| Cash Flow Margin | 28.341 % | |
| Cash Flow To Earnings | 1.36 | |
| VALUE & RETURNS | ||
| Economic Value Added | $ 0.04 | |
| Return On Assets (ROA) | 3.776 % | |
| Return On Assets QoQ | 4.454 % | |
| Return On Assets YoY | 14.702 % | |
| Return On Assets IPRWA | high: 19.773 % LNTH: 3.776 % median: 2.151 % mean: 1.799 % low: -72.965 % |
|
| Return On Capital Employed (ROCE) | 5.961 % | |
| Return On Equity (ROE) | 0.068 | |
| Return On Equity QoQ | 7.724 % | |
| Return On Equity YoY | 11.644 % | |
| Return On Equity IPRWA | high: 0.769 LNTH: 0.068 median: 0.035 mean: 0.001 low: -1.731 |
|
| DuPont ROE | 6.757 % | |
| Return On Invested Capital (ROIC) | 4.754 % | |
| Return On Invested Capital QoQ | 7.459 % | |
| Return On Invested Capital YoY | -154.732 % | |
| Return On Invested Capital IPRWA | high: 20.851 % LNTH: 4.754 % median: 2.936 % mean: 2.92 % low: -30.099 % |
|